Abstract
Our objective was to determine if amphetamine improves visuospatial working memory, which is impaired in the schizophrenia spectrum and may be modulated by dopamine in prefrontal cortex. To this end, oral amphetamine (30 mg) was administered to 12 patients with schizophrenia spectrum personality disorders and 13 patients with other, nonschizophrenia-related personality disorders. Visuospatial working memory was assessed using the Dot test; a test in which subjects are asked to memorize and reproduce the position of a dot on a sheet of paper. Patients with schizophrenia spectrum personality disorders performed significantly worse than the comparison group in the placebo condition and showed significantly greater improvement after amphetamine, as compared to a nonschizophrenia-related personality disorder comparison group. Patients with greatest impairment at baseline improved most. Amphetamine tended to improve negative symptoms; whereas, positive symptoms remained unchanged. Amphetamine may improve visuospatial working memory in schizophrenia spectrum patients.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Angrist B, Rotrosen J, Gershon S . (1980): Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects. Psychopharmacology 67: 31–38
Battaglia M, Bernardeschi L, Franchini L, Bellodi L, Smeraldi E . (1995): A family study of schizotypal disorder. Schiz Bull 21: 33–46
Cornblatt BA, Lezenweger MF, Erlenmeyer-Kimling L . (1989): The continuous performance task, identical pairs version (CPT-IP). II. Contrasting attentional profiles in schizophrenic and depressed patients. Psych Res 26: 65–85
Daniel D, Weinberger D, Jones D, Zigun J, Coppola R, Handel S . (1991): The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci 11: 1907–1917
Ferger B, Kropf W, Kushinsky K . (1994): Studies on electroencephalogram in rats suggest that moderate doses of cocaine or d-amphetamine activate D1 rather than D2 receptors. Psychopharmacology-Berl 114: 297–308
Gold J, Carpenter C, Randolph C, Goldberg T, Weinberger D . (1997): Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch Gen Psychiat 54: 159–165
Goldberg T, Bigelow L, Weinberger D, Daniel D, Kleinman J . (1991): Cognitive and behavioral effects of co-administration of dextroamphetamine and haloperidol in schizophrenia. Am J Psychiat 148: 78–84
Green MF, Marshall BD, Wirshing WC, Ames D, Marder SR, McGurk S, Kern RS, Mintz J . (1997): Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiat 154: 799–804
Green MF . (1996): What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiat 153: 321–330
Kahn RS, Harvey PD, Davidson M, Keefe RSE, Apter S, Neale JM, Mohs RC, Davis KL . (1994): Neuropsychological correlates of central monoamine function in chronic schizophrenia: Relationship between CSF metabolites and cognitive function. Schizophr Res 11: 217–224
Keefe RSE, Silverman J, Mohs R, Siever L, Harvey P, Friedman L, Roitman S, Du Pre R, Smith C, Schmeidler J, Davis K . (1997): Eye tracking, attention and schizotypal symptoms in nonpsychotic relatives of patients with schizophrenia. Arch Gen Psychiat 54: 169–176
Keefe RSE, Roitman SE, Harvey PD, Blum CS, DuPre RL, Prieto DP, Davidson M, Davis KL . (1995): A pen-and-paper human analog of a monkey prefrontal cortex activation task: Spatial working memory in patients with schizophrenia. Schizophr Res 17: 25–33
Kendler KS, Gardner CO . (1997): The risk of psychiatric disorders in relatives of schizophrenic and control probands: A comparison of three independent studies. Psychol Med 27: 411–419
Kendler KS, Diehl SR . (1993): The genetics of schizophrenia. A current genetic epidimiologic perspective. Schiz Bull 19: 261–285
Koenigsberg H, Mitropoulou V, Abi-Dargham A, Nunn M, Laruelle M, Siever L . (1999): Subcortical dopamine activity in schizotypal personality disorder. Presented as an NR abstract at the 152nd annual APA Meeting, Washington DC.
Laruelle M, Abi-Dargham A, Van Dyck C, Gil R, D'Souza C, Erdos J, McCance E, Rosenblatt W, Fingado C, Zogbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB . (1996): Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic patients. Proc Natl Acad Sci USA 93: 9235–9240
Lees Roitman SE, Keefe RSE, DuPre RL, Siever L . (1996): Visuospatial working memory in schizotypal personality disorder. Abstract #266, Society of Biological Psychiatry Annual Meeting, 1996.
Park S, Holzman PS . (1992): Schizophrenics show spatial working memory deficits. Arch Gen Psych 49: 975–982
Park S, McTigue K . (1997): Working memory and the syndromes of schizotypal personality. Schizophr Res 26: 213–220
Siegel BV, Trestman RL, O'Flaithbheartaigh S, Mitropoulou V, Amin F, Kirrane R, Silverman JM, Schmeidler J, Keefe RSE, Siever L . (1996): D-amphetamine challenge effects on Wisconsin Card Sort Test. Performance in schizotypal personality disorder. Schizophr Res 20: 29–32
Siever L, Kalus OF, Keefe RSE . (1993): The boundaries of schizophrenia. Psychiat Clin N Am 16: 217–244
Trestman RL, Keefe RSE, Mitropoulou V, Harvey PD, deVegvar ML, Losonczy MF, Lees-Roitman S, Davidson M, Aronson A, Silverman J, Siever LJ . (1995): Cognitive function and biological correlates of cognitive performance in schizotypal personality disorder. Psychiat Res 59: 127–136
van Kammen DP, Bunney WE, Docherty JP, Marder S, Ebert MH, Rosenblatt JE, Rayner JN . (1982): d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia. Am J Psychiat 139: 991–997
Weinberger DR, Lipska BK . (1995): Cortical maldevelopment, antipsychotic drugs, and schizophrenia: A search for common ground. Schizophr Res 16: 87–110
Williams GV, Goldman-Rakic PS . (1995): Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 376: 572–575
Acknowledgements
This work was supported in part by a VA Postdoctoral Research Training Award to Dr. Kirrane, NIMH Grant RO1-MH 56140, and VA Merit award to Dr. Siever, and NIH SMO1 RR00071 to the Mount Sinai Hospital General Clinical Research Center.
Author information
Authors and Affiliations
Additional information
This work was presented at the American Psychiatric Association Annual Meeting, San Diego, CA, May 17–22, 1997
Rights and permissions
About this article
Cite this article
Kirrane, R., Mitropoulou, V., Nunn, M. et al. Effects of Amphetamine on Visuospatial Working Memory Performance in Schizophrenia Spectrum Personality Disorder. Neuropsychopharmacol 22, 14–18 (2000). https://doi.org/10.1016/S0893-133X(99)00075-5
Received:
Revised:
Accepted:
Issue date:
DOI: https://doi.org/10.1016/S0893-133X(99)00075-5
Keywords
This article is cited by
-
Effects of the D1 Dopamine Receptor Agonist Dihydrexidine (DAR-0100A) on Working Memory in Schizotypal Personality Disorder
Neuropsychopharmacology (2015)
-
Remediation and Cognitive Enhancers in Schizotypal Personality Disorder
Current Treatment Options in Psychiatry (2014)
-
SSR504734 enhances basal expression of prepulse inhibition but exacerbates the disruption of prepulse inhibition by apomorphine
Psychopharmacology (2013)
-
The amphetamine sensitization model of schizophrenia: relevance beyond psychotic symptoms?
Psychopharmacology (2009)
-
Persönlichkeitsstörungen – Diagnostische Konzepte – Neurobiologie-Pharmakotherapie
Psychiatrie und Psychotherapie (2008)
